Funding for this research was provided by:
National Natural Science Foundation of China (81373822)
the Cooperation Fund of the Institute of Cardiovascular Diseases of China Academy of Chinese Medical Sciences and Kanghong pharmaceutical (KHZYSC2015070704-B)
Text and Data Mining valid from 2019-04-15
Received: 20 March 2018
Accepted: 19 March 2019
First Online: 15 April 2019
Ethics approval and consent to participate
: The study is in compliance with the Declaration of Helsinki (Edinburgh 2000 version). Only clinicians holding the necessary qualifications are acting as principal investigators. The final amendments (version: March 25, 2017) and the consent form have been reviewed and approved by the Ethics Committee of Xiyuan Hospital of China Academy of Chinese Medical Sciences (reference number: 2016XL007-3). If there is any amendment to the protocol, approval must be again sought from the Ethics Committee. Written informed consent will be obtained from each participant before enrolment.
: We obtained informed consent for publication of the dataset from the patients at the point of recruitment to the trial. All patients will be completely anonymous.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.